Publications by authors named "Daniela Barbero"

Claim this Profile
A
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial.
Gian Maria Zaccaria, Simone Ferrero, Eva Hoster, Roberto Passera, Andrea Evangelista, Daniela Barbero

Cancers (Basel)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of different exposure models and spatial resolution on the long-term effects of air pollution.
Claudio Gariazzo, Giuseppe Carlino, Camillo Silibello, Gianni Tinarelli, Matteo Renzi, Daniela Barbero

Environ Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
Irene Della Starza, Lucia Anna De Novi, Marzia Cavalli, Noemi Novelli, Roberta Soscia, Daniela Barbero

Hematol Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
mutations and disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
Simone Ferrero, Davide Rossi, Andrea Rinaldi, Alessio Bruscaggin, Valeria Spina, Daniela Barbero

Haematologica· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
Irene Della Starza, Marzia Cavalli, Lucia Anna De Novi, Elisa Genuardi, Barbara Mantoan, Daniela Barbero

Hematol Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes.
Gian Maria Zaccaria, Simone Ferrero, Samanta Rosati, Marco Ghislieri, Elisa Genuardi, Daniela Barbero

JCO Clin Cancer Inform· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up.
Paola Ghione, Elisa Genuardi, Davide Rossi, Daniela Drandi, Barbara Mantoan, Daniela Barbero

Br J Haematol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data.
Marco Beccuti, Elisa Genuardi, Greta Romano, Luigia Monitillo, Daniela Barbero

BMC Bioinformatics· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
Carlo Visco, Annalisa Chiappella, Luca Nassi, Caterina Patti, Simone Ferrero, Daniela Barbero

Lancet Haematol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.
Daniela Drandi, Lenka Kubiczkova-Besse, Simone Ferrero, Nadia Dani, Roberto Passera, Daniela Barbero

J Mol Diagn· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance.
Irene Della Starza, Marzia Cavalli, Ilaria Del Giudice, Daniela Barbero, Barbara Mantoan

Hematol Oncol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.
Simone Ferrero, Luigia Monitillo, Barbara Mantoan, Daniela Barbero, Elisa Genuardi

Ann Hematol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma.
Chiara Lobetti-Bodoni, Barbara Mantoan, Luigia Monitillo, Elisa Genuardi, Daniela Drandi, Daniela Barbero

Ther Adv Hematol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment.
Chiara Lobetti-Bodoni, Dario Ferrero, Elisa Genuardi, Roberto Passera, Elisa Bernocco, Daniela Barbero

Mech Ageing Dev· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IGF-I induces caveolin 1 tyrosine phosphorylation and translocation in the lipid rafts.
Davide Maggi, Claudia Biedi, Daniela Segat, Daniela Barbero, Danilo Panetta

Biochem Biophys Res Commun· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis